

PARKS Parkinson's Signature Biomarker Test

Parkinson's Disease (PD) is the fastest growing neurological disorder worldwide. As there is no **biomarker** for PD, current diagnosis takes a long time and diagnosis can be inaccurate. This limits success in **clinical trials**, because of undefined patient stratification.

PARKS aims to enable quick, and accurate diagnosis of the disease, based on measuring the levels of specific protein signatures. It hopes to eventually facilitate disease follow-up, and allow personalized treatment plan leading to better life quality for patients and improved clinical trial outcome.

Eleanor Coffey, Ph.D. Research Director at Turku Bioscience Centre, Åbo Akademi University in Finland.



The PARKS team gathers experts in neurobiology, mass-spectrometry and computational medicine. Our steering board includes world leaders from the biotech industry.

SPARK VALUE: We are excited to participate in the SPARK mentoring program. They have provided immediate feedback to keep our business goals “on-point” and shared network contacts that have been of great practical benefit in Finland and abroad.